Short Interest in ChromaDex Co. (NASDAQ:CDXC) Grows By 6.7%

ChromaDex Co. (NASDAQ:CDXC) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,070,000 shares, an increase of 6.7% from the December 15th total of 1,940,000 shares. Based on an average trading volume of 1,270,000 shares, the days-to-cover ratio is currently 1.6 days. Approximately 4.3% of the shares of the stock are sold short.

Insider Buying and Selling at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On ChromaDex

Several institutional investors have recently modified their holdings of CDXC. SG Americas Securities LLC raised its holdings in ChromaDex by 42.5% during the 4th quarter. SG Americas Securities LLC now owns 23,857 shares of the company’s stock valued at $127,000 after buying an additional 7,117 shares during the period. USA Financial Formulas bought a new position in ChromaDex during the fourth quarter valued at $25,000. JPMorgan Chase & Co. raised its stake in shares of ChromaDex by 11.1% in the third quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock valued at $1,211,000 after acquiring an additional 33,150 shares during the period. Franklin Resources Inc. bought a new stake in shares of ChromaDex in the 3rd quarter worth about $68,000. Finally, Barclays PLC boosted its stake in shares of ChromaDex by 322.1% during the 3rd quarter. Barclays PLC now owns 70,072 shares of the company’s stock worth $256,000 after purchasing an additional 53,472 shares during the period. 15.41% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on CDXC shares. HC Wainwright upped their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Roth Mkm raised their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, StockNews.com cut ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Wednesday.

ChromaDex Trading Up 5.1 %

CDXC traded up $0.29 during trading hours on Friday, hitting $5.94. The company’s stock had a trading volume of 364,834 shares, compared to its average volume of 436,868. The stock has a market cap of $453.70 million, a price-to-earnings ratio of 594.59 and a beta of 2.21. The business’s 50-day moving average price is $6.34 and its 200-day moving average price is $4.45. ChromaDex has a 12 month low of $1.36 and a 12 month high of $7.97.

ChromaDex (NASDAQ:CDXC) last announced its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $25.58 million for the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period in the prior year, the company earned ($0.01) EPS. On average, analysts forecast that ChromaDex will post 0.04 earnings per share for the current year.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.